Minerva Neurosciences (NERV) Long-Term Investments (2015 - 2017)
Minerva Neurosciences' (NERV) quarterly Long-Term Investments came in at $5.0 million in Q4 2017, down 51.49% on a QoQ basis from $10.4 million in Q3 2017.
Powered by 
Analysis
Minerva Neurosciences (NERV) Long-Term Investments (2015 - 2017) Analysis & Trends
Minerva Neurosciences (NERV) has 2 years of Long-Term Investments data on file, last reported at $5.0 million in Q4 2017.
- Quarterly Long-Term Investments changed N/A year-over-year to $5.0 million in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $5.0 million (changed N/A YoY) and the FY2017 annual result came in at $5.0 million, changed N/A from the prior year.
- Long-Term Investments retreated to $5.0 million in Q4 2017, from $10.4 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $10.4 million in Q3 2017 to a low of $1.4 million in Q3 2015.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -4.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1.77 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.17 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 372.10 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Minerva Neurosciences | 207.37 Mn | 207.37 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2017 | 5.02 Mn |
| Sep 30, 2017 | 10.36 Mn |
| Sep 30, 2015 | 1.41 Mn |
| Jun 30, 2015 | 9.44 Mn |